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Abstract 
 Antibiotic resistance is a prevalent problem in modern society, with almost three million 
cases of antibiotic resistant infections occurring yearly in the U.S.1 When antibiotics were 
developed as a treatment for disease and infection, most bacteria were susceptible to their antibiotic 
properties. However, over time, as a result of over-prescription and misuse of the drugs, bacteria 
have developed resistance to the medications. β-lactam antibiotics are a common and effective 
class of antibiotics, but they too are losing potency as more bacteria develop resistance to them in 
the form of β-lactam hydrolysis caused by β-lactamase. β-lactamase is an enzyme that catalyzes 
the cleavage of the β-lactam ring of penicillin antibiotics, rendering them ineffective. 
 The goal of this project is to create sensing systems that can monitor the hydrolysis of β-
lactam antibiotics. The systems will utilize a fusion protein of β-lactamase and enhanced green 
fluorescent protein (EGFP). β-lactamase, an enzyme responsible for conferring antibiotic 
resistance, is encoded in the ampicillin resistance (ampr) gene of many plasmids. The β-lactam 
ring of penicillins gives the antibiotics their effectiveness by inhibiting cell wall synthesis during 
bacterial replication. When β-lactamase catalyzes the cleavage the β-lactam ring, a proton is 
released, decreasing the local pH. EGFP, a variant of green fluorescent protein (GFP), is a pH-
sensitive fluorescent protein that will be used as the reporter protein to monitor the hydrolysis of 
the β-lactam ring. EGFP has two key mutations in the chromophore region that result in its 
fluorescence being more intense than that of GFP when excited at 488 nm and allows it to respond 
to changes in pH. In the assays being developed, the EGFP domain of the fusion protein will 
respond to the drop in local pH resulting from the β-lactam hydrolysis, leading to a decrease in 
fluorescence over time. 
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 This project has three directions. The first is the recreation of the in vitro fusion protein 
from the original study to be used for comparison.50 The second is the validation of the pH theory 
with the β-lactamase and EGFP proteins being expressed individually and added separately for the 
assay to demonstrate that the proteins must be in immediate proximity for a decrease in 
fluorescence to occur. The third is the development of an in vivo whole-cell based system using a 
fusion protein of β-lactamase and EGFP to measure the bioavailability of new β-lactam antibiotics. 
These aims will be met by isolating the β-lactamase and EGFP genes from a source plasmid, 
amplifying the genes via polymerase chain reaction (PCR), digesting the genes using restriction 
enzymes, ligating them into vectors, and transforming them into DH5α competent E. coli bacterial 
cells. After successful transformation of the individual and fusion genes into the E. coli cells, the 
DNA will be sequenced. If the results of sequencing confirm the presence of the target genes, large 
scale cultures of bacteria expressing the in vivo fusion will be created, and the proteins will be 
purified. Fluorescence assays will be performed on the purified proteins to study their fluorescence 
characteristics.  
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Introduction 
Biosensors 
 A sensor is “a device that responds to physical stimulus (such as heat, light, sound, 
pressure, magnetism, or a particular motion) and transmits a resulting impulse (as for measurement 
or operating a control).”2 Sensors accomplish this using a recognition element and a transducer. 
The recognition element responds to changes, and the transducer converts the change into an 
electronic signal to allow changes in the system to be observed.3 
 Biosensors are a class of sensor that are of interest in this project. A biosensor is an 
analytical device that “monitors and transmits information about a life process; especially: a device 
consisting of a biological component (such as an enzyme or bacterium) that reacts with a target 
substance… and emits a signal.”4 The biological component of biosensors acts as the recognition 
element, and can be an enzyme, antibody, nucleic acid, or receptor, making biosensors more 
selective and sensitive than other sensors. Biosensors are so sensitive that detections have been 
made in the femtomolar range.6 The transducer element is generally based on a reporter protein.5 
Using fluorescent reporter proteins, quantitative measurements can be made through fluorescence 
analysis in whole cell-based sensing systems, such as by flow cytometry.7  
 Biosensors were first used in 1962 for the enzymatic measurement of blood glucose levels 
using oxygen electrodes to observe the products of glucose oxidase.8 Since then, they have 
experienced many diverse applications. Potentiometric enzyme electrodes with urease are used to 
measure urea levels. Fiberoptic sensors are used for the in vivo measurement of blood gas levels.9 
Potentiometric alternating biosensors are used in the detection of pathogens on foods, and 
enzymatic biosensors are used in the detection of organophosphate pesticides in milk. Medically, 
glucose biosensors are used for at-home monitoring of blood glucose levels in individuals with 
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diabetes mellitus. Fluorescence biosensors are used as imaging agents in cancers and drug 
discovery.8 More relevant to this research, GFP fluorescent protein biosensors have been applied 
to microphysiological systems to monitor enzymatic activity and metabolite production.10 
 In this research, the aim is the creation of sensing systems to measure enzymatic activity 
of β-lactamase. Sensing systems are a class of sensors that are not “true” sensors, but function 
similarly. Sensing systems do not utilize an internal transducer, but rather an outside element to 
measure signals.11 There are three primary classes of biosensing systems: molecular, cellular, and 
tissue based. The system used in this research is a whole cell-based biosensing system. Cellular-
based systems are advantageous in that they are stable in environments with varying temperature 
and pH, making them physiologically relevant and allow for bioavailability studies.12,13 Whole 
cell-based biosensing systems use a variety of fluorescent reporter proteins, commonly including 
GFP, aequorin, firefly luciferase, bacterial luciferase, and red fluorescent protein.10,13  
β-lactam Antibiotics 
 Penicillin, a commonly used β-lactam antibiotic, was first discovered in 1928 by Alexander 
Fleming. Fleming had been culturing colonies of Staphylococcus, and he noticed that on one dish, 
a mold was growing. The dish was covered with Staphylococcus colonies, except for the area 
directly surrounding the mold – the zone of inhibition. The mold was later identified as Penicillium 
notatum. It had secreted a liquid that killed and prevented the growth of bacteria. Further 
experimentation by Fleming showed that the liquid secreted was an effective treatment against 
other common pathogenic bacteria, such as Streptococcus and meningococcus (the bacterium 
responsible for meningococcal meningitis), displaying the toxicity of penicillin towards both 
Gram-positive and Gram-negative bacteria.14 
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 β-lactam antibiotics, also known as penicillins, have a key feature that gives them their 
effectiveness, a β-lactam ring. The ring feature was discovered in 1945.14 Figure 1 below depicts 
the four membered ring containing nitrogen and a carbonyl group. 
 
Figure 1. Structure of penicillin with four-membered β-lactam ring encircled 
There are a variety of antibiotics that contain the β-lactam ring; they are grouped into four 
classes based on the varying substituents surrounding the β-lactam ring structure: penicillins, 
cephalosporins, monobactams, and carbapenems.15 Figure 2 below depicts representative 
structures of each class of the antibiotics. 
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Figure 2. Structure of penicillins, cephalosporins, monobactams, and carbapenems; the β-lactam 
ring is highlighted in red in each structure 
 
 The mechanism of action of β-lactam antibiotics is for the β-lactam ring to covalently bind 
to and inhibit transpeptidases, carboxypeptidases, and endopeptidases, all essential enzymes in the 
terminal phases of peptidoglycan cell wall biosynthesis. Due to the affinity of the enzymes for β-
lactam antibiotics, they are referred to as penicillin-binding protein (PBPs). PBPs catalyze the 
reaction that allows the cross-linking of peptidoglycan chains during cell wall synthesis, but this 
reaction will not occur in the presence of β-lactam antibiotics. With no cell wall present, the 
bacteria cannot grow or replicate, and are signaled for autolysis.16 
β-lactamase 
 Resistance to β-lactam antibiotics is growing for several reasons - two main ones being 
over-prescribing by doctors and patients failing to follow proper prescription protocols, allowing 
bacteria to adapt to the drugs by propagation of the ampr gene to survive and reproduce, spreading 
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the resistance.17 The enzyme that gives resistance to β-lactam antibiotics is penicillinase, also 
known as β-lactamase. β-lactamase is a hydrolase enzyme that catalyzes the cleavage of the β-
lactam ring in penicillins. Once the ring is cleaved, the antibiotic will no longer be able to bind to 
the peptidoglycan cell wall synthesis enzymes, rendering it ineffective.16 Figure 3 below depicts 
the crystal structure of β-lactamase. The enzyme contains 263 amino acids and has a mass of 29 
kDa. It contains 13 helices – four 310 helices and nine α-helices – and nine β-strands, with two 3-
strand β-sheets.18 
 
Figure 3. Class A β-lactamase structure from Escherichia coli complexed with a penicillin. PDB 
ID 5NE3 “L2 class A serine-beta-lactamase complexed with avibactam”18  
 
There are four classes of β-lactamase enzymes based on their hydrolytic functionality – A, 
B, C, and D. Classes A, C, and D are serine-based enzymes that cleave peptide bonds in proteins 
using serine as the nucleophilic amino acid in the active site, whereas class B β-lactamases are 
metalloenzymes that use one or two zinc ions as catalysts.  With greater than 550 known enzymes, 
class A β-lactamases are the most abundant of the four classes. Despite the differences in the 
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enzymes, all four classes are thought to be evolutionarily related, and they all catalyze the same 
reaction.19,20 
 Shortly after the introduction of β-lactam antibiotics, bacterial expression of β-lactamase 
became prominent. In 1941, almost all strains of Staphylococcus aureus were susceptible to 
penicillin, but many had become resistant by 1944. Currently, more than 95% of Staphylococcus 
a. strains are resistant to β-lactam antibiotics due to β-lactamase expression. β-lactamase is 
produced more abundantly in Gram-positive bacteria, but Gram-negative bacteria exhibit the 
enzyme expression as well. 21. A major reason for the rapid, widespread expression of β-lactamase 
is that the gene encoding the enzyme can be found in the primary chromosomal DNA, or the 
secondary plasmid DNA.22 Plasmid DNA is commonly transferred between bacteria, both 
intraspecifically and interspecifically, by bacterial conjugation, allowing the ampr gene to be 
spread with little deterrence.23 
 β-lactamase is commonly used as a selectable marker in molecular biology, DNA 
recombination, and genetic engineering. Genes are amplified, digested, and ligated into vector 
plasmids to construct a recombinant plasmid to be transformed into bacterial cells. Because the 
enzyme allows for bacterial growth on selective media containing ampicillin antibiotic, it can be 
used to identify successful transformations and propagation of target genes for efficient DNA 
cloning.24 
β-lactam antibiotics have numerous benefits. Due to this, much research has been done to 
find ways to deactivate β-lactamase for the continued use of antibiotics, in spite of increasing 
resistance. A popular method is the administration of cocktails containing β-lactamase inhibitors 
alongside β-lactam antibiotics. For example, Augmentin is a cocktail that contains amoxicillin and 
clavulanic acid. β-lactamase inhibitors are drugs that block the activity of β-lactamase, preventing 
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the degradation of β-lactam antibiotics. These β-lactamase inhibitors have very little antibiotic 
activity on their own but serve a supplemental purpose for antibiotics, allowing it to interact with 
target bacteria even if they express β-lactamase. The inhibitors contain a β-lactam ring which 
allows them to bind in the active site of the β-lactamase enzyme. Once bound, the inhibitors 
undergo a conformational change to create a more reactive species that attacks other amino acids 
in the active site, inactivating the β-lactamase enzyme. Common examples of β-lactamase 
inhibitors are clavulanic acid, sulbactam, and tazobactam. These molecules contain a β-lactam ring 
like those found in β-lactam antibiotics. β-lactamase binds to the inhibitor, leaving less enzyme 
available to catalyze the cleavage of the β-lactam ring in the antibiotics.25 Figure 4 below depicts 
the structures of the inhibitors. 
Figure 4. Structure of β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam; the β-
lactam ring structure is highlighted in red 
 
Green Fluorescent Protein (GFP) and Enhanced Green Fluorescent Protein (EGFP) 
 In the first century A.D., a Roman natural philosopher, Pliny the Elder, described the green 
light emitted by glowing jellyfish in the Mediterranean Sea. He noted that the slime could be 
removed from the jellyfish and the luminescence transferred to other objects.26 It was not until 
1962 that GFP was first discovered and isolated from the jellyfish, Aequorea victoria, by 
Shimomura, Johnson, and Saiga.27 In the jellyfish Aequorea v., GFP fluoresces when luminescent 
energy from the bioluminescence of aequorin, a blue luminescent protein, is transferred to it as a 
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result of Förster resonance energy transfer (FRET).28 FRET is the transfer of energy between two 
chromophores – a donor in its excited electronic state and an acceptor – as a result of radiationless 
dipole-dipole coupling.29 Figure 5 below depicts the jellyfish Aequorea v. 
 
Figure 5. Aequorea victoria jellyfish with GFP green fluorescence30 
 
GFP is used as a quantitative reporter protein, as its pH-dependent fluorescence can be 
measured using a spectrofluorometer. GFP has stable fluorescence from pH 6 to 10, but 
fluorescence decreases at pH < 5 and increases at pH > 10.31 It is often used as the reporter 
protein of choice over other luminescent reporter proteins (such as aequorin and luciferase), 
because it is stable at biological pHs and is autofluorescent. The autofluorescence is the result of 
three amino acid residues – Ser65, Tyr66, and Gly67 – in the central α-helix that form the 
chromophore region of GFP.32 GFP has two excitation peaks – a λmax at 395 nm and a second at 
475 nm – and an emission peak at 509 nm, giving the protein its green fluorescence.33 The 
utilization of GFP is also advantageous in that it retains its fluorescence properties when 
expressed in a species from which it did not originate.34 Due to their stabilities at normally 
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denaturing conditions, such as basic pH, high salinity, and in the presence of organic solvents 
and detergents, GFP and its variants have been expressed in many species, including bacteria, 
plants, and animals. Figures 6 and 7 below depicts examples of GFP expression in various 
organisms. 
 
Figure 6. Transgenic rhesus monkeys expressing EGFP under ambient light and under UV light35 
 
 
Figure 7. Transgenic animals, plants, and cells expressing GFP under UV light36 
 
 GFP has many applications as a reporter protein. It does not lose its fluorescence when 
fused to another protein, making it very useful to monitor localization of proteins, and it can be 
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used for non-invasive measurements of gene expression, protein localization, intracellular protein 
targeting, and pH by observing its fluorescence.37,38 This has allowed for GFP to be used in the 
study of gene transfer in human stem cells and bacterial transformations.39 Sensing systems using 
GFP and GFP derivatives have been used to detect lysine content, calcium binding proteins, L-
arabinose, copper, lead, and cadmium, highlighting the diverse applications of GFP as a 
reporter.34,40,41  
 GFP has a size of 26.9 kDa and is comprised of 238 amino acid residues.42 The protein 
contains 11 β-sheets arranged in a β-barrel formation with a diameter of 24 to 30 Å.32,43,44 The β-
barrel is almost perfectly symmetrical, with a flaw in the seventh and eighth strands that is believed 
to be necessary for proper protein folding since the β-barrel forms before the chromophore region 
folds into its active form.45 The chromophore region consists of Ser65, Tyr66, and Gly67 residues in 
the central α-helix of the protein.32 The β-barrel structure protects the chromophore region, which 
gives it stability in the denaturing conditions previously described.45 Figure 8 below depicts the 
structure of GFP. 
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Figure 8. Ribbon structure of GFP with the fluorescent chromophore highlighted in yellow. PDB 
ID 1EMA “GREEN FLUORESCENT PROTEIN FROM AEQUOREA VICTORIA”45 
 
Wild type GFP (wtGFP), while useful, could be improved upon. It has a low brightness, a 
delay between protein synthesis and fluorescence emergence, and complex photoisomerization.46 
Due to this, variations of GFP were developed for use in research. Examples are enhanced green 
fluorescent protein (EGFP), enhanced blue fluorescent protein (EBFP), blue fluorescent protein 2 
(BFP2), enhanced yellow fluorescent protein (EYFP), enhanced cyan fluorescent protein (ECFP)), 
and GFPuv (18 times brighter than wtGFP).47 The various spectral properties of the variants mean 
they have their own unique signatures, their emission wavelengths. This is useful to tag different 
proteins with the variants and allows for simultaneous detection of multiple proteins. Like GFP, 
each of the variant’s fluorescence is also pH dependent. 
EGFP, a red-shifted variant of GFP mentioned above, is used in this research. EGFP has 
two key mutations that shift its excitation maximum from 395 nm to 488 nm and increases its 
 21 
fluorescence intensity. EGFP fluoresces 35 times brighter than GFP when excited at 488 nm, 
making it much more desirable than GFP for laboratory studies.39 The increase in fluorescence 
intensity is the result of an increase in extinction coefficient caused by the two mutations. The 
mutations are F64L just outside the chromophore region and S65T just within the chromophore 
region. The mutations make it more useful in lab work as the argon laser, which emits light at 488 
nm, is one of the most common instrumental lasers. The 488 nm wavelength is also very common 
in filter sets for many analytical instruments.47  
The fluorescence of EGFP can also be used to quantitatively measure gene expression in 
specifically designed systems due to its pH-dependent fluorescence. This is the result of the 
protonation state of a hydroxyl group in the chromophore region of EGFP. When deprotonated at 
a high pH, there is a high level of fluorescence due to a greater abundance of electrons in the 
system. When it is protonated at a low pH, there is a low level of fluorescence due to a lower 
abundance of electrons in the system.48 EGFP is also beneficial in that the mutations optimize the 
protein for expression in mammalian cells.47 Over the years, EGFP and other GFP variants have 
been expressed in normal lab animals, such as mice and monkeys, and even in household animals, 
such as cats and dogs. Figure 9 below depicts the pH-dependent fluorescence of EGFP. 
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Figure 9. The pH-dependent fluorescence of GFP variants49 
 
 EGFP fluorescence is dependent on the concentration of EGFP as well. The concentration 
and fluorescence have a linear relationship up to an absorbance of 0.05, but the linearity is then 
lost. However, the relationship still follows a predictable, logarithmic relationship after. Figure 10 
below depicts the linear and logarithmic relationship. 
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Figure 10. Relationship of fluorescence vs. concentration of EGFP-β-lactamase fusion protein50 
 
Principle of the Assays  
The pH theory states that for a sensing system to be effective, the genes for β-lactamase 
and EGFP must be directly fused together so that they are in close enough proximity for the 
decrease in local pH to impact the fluorescence of the EGFP domain. An in vitro construct of β-
lactamase will be recreated. There is an expected decrease in fluorescence over time as β-
lactamase cleaves the β-lactam rings of ampicillin, leading to a local pH around the fusion 
protein. The genes will be isolated and expressed separately. The lack of close-proximity will 
result in β-lactamase activity having no effect on the fluorescence of EGFP, because the local pH 
around β-lactamase is decreasing, but the bulk pH remains unchanged and EGFP is not close 
enough to β-lactamase for the local pH change to affect it. An in vivo construct of β-lactamase 
and EGFP will be constructed to be expressed in a whole-cell sensing system. Like the in vitro 
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fusion protein, there is an expected decrease in fluorescence over time as a result of the direct 
proximity of the β-lactamase and EGFP domains of the fusion protein. Figure 11 below depicts a 
summary of the principle of the assays. 
 
Figure 11. Summary of the principle of the in vitro, individual, and in vivo assays. 
 
In Vitro Fusion Protein 
 In this portion of the project, the original in vitro fusion protein, created by Puckett et. al., 
will be recreated. pEGFP, the source plasmid for β-lactamase and EGFP genes, is isolated from 
stock cultures, and the genes for β-lactamase and EGFP are selectively amplified using polymerase 
chain reaction (PCR). Rather than just amplifying the genes alone, a tail containing a restriction 
site will be placed on one end of the sequences for β-lactamase and EGFP, and a spacer region 
will be placed at the other ends of the genes, depicted in Figure 12 below. Following the first round 
of PCR, a second, overlap extension PCR will be run to fuse the two genes into one, using the 
spacer region to facilitate the fusion. For the in vitro fusion protein, the EGFP gene will be placed 
before the β-lactamase gene. After being fused together, the fusion gene will be digested using 
HindIII and EcoRI restriction enzymes and ligated into a pFLAG-MAC expression vector for 
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transformation into E. coli cells. Figure 12 below depicts a summary of the in vitro fusion portion 
of the project.  
 
 
 
 
Figure 12. Amplification, digestion, and ligation of in vitro fusion protein into pFLAG-MAC 
vector plasmid 
 
  
 
Digestion and 
Ligation 
HindIII 
HindIII 
EcoRI 
EcoRI 
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Validation of the pH Theory 
 In this portion of the project, the genes for β-lactamase and EGFP are isolated and 
amplified individually. Rather than fusing the two together, they are digested using HindIII and 
EcoRI restriction enzymes and ligated into separate pFLAG-MAC expression vectors to create 
two new plasmids -- pLP003 and pLP004 -- for transformation into Escherichia coli to validate 
the local pH theory. Figure 13 below depicts a summary of the digestion and ligation of the 
individual genes into the pFLAG-MAC expression vectors. 
Figure 13. Digestion and ligation of β-lactamase and EGFP, individually, into pFLAG-MAC for 
validation assay 
 
For the first two portions of the project -- the individual portion and the in vitro portion -- 
the vector plasmid pFLAG-MAC was chosen. The presence of a FLAG affinity octapeptide tag 
allows the use of anti-FLAG affinity gels to aid in purification of the proteins from cellular 
material. 
 
 
HindIII HindIII 
EcoRI EcoRI 
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In Vivo Fusion Protein 
 The molecular biology techniques used in the creation of the in vivo fusion protein portion 
of the project are very similar to those used in the in vitro portion. There are three primary 
differences; the order of the genes, the expression vector used, and the restriction enzymes used 
during the digestion. 
 During the in vitro portion of the project, the EGFP gene was inserted upstream of the β-
lactamase gene. Because the fluorescence of EGFP domain of the fusion protein was studied in 
vitro, the order of the genes did not matter. However, in the in vivo portion of the project, the 
fusion protein must be expressed in the periplasm of the cell so that interactions with antibiotics 
crossing the cell membrane will occur. The gene for β-lactamase contains a signal peptide that 
directs the protein to the periplasm, so the β-lactamase gene must be upstream of the EGFP gene. 
For that reason, the order of the genes becomes extremely important. Figure 14 below depicts the 
order of the genes in the in vitro and in vivo portions of the project. 
          
            In Vitro                                                                       In Vivo with Signal Peptide 
Figure 14. In vitro and in vivo fusion genes with signal peptide present on β-lactamase gene for in 
vivo fusion gene 
 
 For the in vitro portion of the project, pFLAG-MAC was being used as the expression 
vector because pFLAG-MAC contains the ampr gene. For the in vivo portion, an expression vector 
had to be used that did not encode for ampicillin resistance, because the fusion gene should contain 
the only hydrolytic activity for β-lactamase. pET28b was chosen as the new expression vector, 
because it encodes for kanamycin resistance, allowing the confirmation of a successful ligation 
and transformation if the transformed E. coli cells were able to grow in the presence of kanamycin. 
The ampicillin resistance can be identified as a property of the insert, and not the expression vector. 
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Figure 15 below depicts the recombinant pET28b vector plasmid with the in vivo fusion protein 
ligated in. 
 
Figure 15. pET28b plasmid with in vivo fusion gene inserted 
 
 During the in vitro portion of the project, the restriction enzymes used were EcoRI and 
HindIII. For the in vivo portion of the project, the restriction enzymes used were HindIII and XhoI. 
The purpose of using XhoI, as opposed to EcoRI, during the in vivo portion is that in the pET28b 
vector plasmid, the HindIII restriction site falls before the XhoI restriction site. EcoRI was not used 
because it falls before the HindIII restriction site. It made it easier to keep things organized between 
the in vitro and in vivo portions to use a different enzyme set. Figure 16 below depicts the in vivo 
fusion gene with the HindIII and XhoI restriction sites attached to tails of the gene. 
 
Figure 16. In vivo fusion gene with HindIII and XhoI restriction sites attached 
 
HindIII 
XhoI 
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 The in vivo fusion gene above will be ligated into the pET28b vector plasmid. Restriction 
enzymes in will be used to digest the plasmid and the in vivo fusion gene to generate “sticky-ends” 
that will allow the fusion gene to be inserted into the vector plasmid. In pET28b, the restriction 
site for HindIII falls upstream of XhoI; β-lactamase will be transcribed prior to EGFP. Once 
translated, the signal peptide will direct the protein to the periplasm of the cell, where the expressed 
fusion protein can react with ampicillin that crosses the cell membrane. The local pH will decrease 
as a proton is released with each cleavage event. EGFP is a pH-dependent fluorescent protein, so 
as β-lactamase activity increases, the drop in local pH will lead to decreased fluorescence. Figure 
17 below depicts a representation of the of the protein being directed to the periplasm and the 
fluorescence over time expected as the fusion protein is active. 
 
Figure 17. Representation of fusion protein in the periplasm of cell and expected change in 
fluorescence over time of fusion protein activity 
 
Previous Work on this Project 
 Prior to the start of this research, work had already been completed on the project. A major 
accomplishment was the creation of the EGFP-β-lactamase fusion protein to be used for in vitro 
fluorescence studies. Figure 18 below depicts the gene, cloned in the vector plasmid pFLAG-
MAC. Using this fusion protein, it was verified that the hydrolysis of β-lactam antibiotics by β-
lactamase can be monitored over time using the pH-dependent fluorescence of EGFP.50 
Ampicillin 
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Figure 18. Plasmid pSD4001 with expression of EGFP-β-lactamase fusion gene50 
 
 This plasmid has been transformed into DH5α competent E. coli cells, protein expression 
induced with isopropyl β-D-1-thiogalactopyranoside (IPTG), and the protein purified with anti-
FLAG affinity gel. In vitro studies were completed using this protein. The EGFP domain of the 
fusion protein was demonstrated to retain the pH-dependent fluorescence when fused to β-
lactamase. Figure 19 below depicts the pH-dependent fluorescence of the in vitro fusion protein. 
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Figure 19. pH-dependent fluorescence of in vitro fusion protein; decreased pH leads to decreased 
fluorescence 
 
An important study that was performed looked at the protein’s response to ampicillin (a β-
lactam antibiotic); as the ampicillin interacted with the β-lactamase domain of the fusion protein, 
the β-lactam ring was cleaved, releasing a proton, lowering the local pH of the system. The EGFP 
domain of the fusion protein responded to the lowered pH with a decrease in the intensity of the 
fluorescence, this interaction is illustrated in the data collected by Puckett et. al.50 Figure 20 below 
depicts the decrease in fluorescence in response to the decrease in pH.  
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Figure 20. Change in fluorescence over time as a result of fusion protein-ampicillin interaction50 
 
 A portion of this research is seeking to replicate this data in order to compare results from 
utilizing the individual proteins. The separate proteins will be added together at the same 
concentration of the fusion protein. It is hypothesized that the two proteins must be in close 
proximity (fused together) in order to monitor the local pH change that occurs with β-lactam 
hydrolysis. 
Aim of Project 
 The in vitro EGFP-β-lactamase fusion protein will be recreated to confirm previous 
findings and to validate the pH theory. An in vivo β-lactamase-EGFP fusion protein will be 
constructed to be used in a whole-cell sensing system. 
After the β-lactamase-EGFP in vivo fusion gene has been successfully cloned and 
transformed into DH5α competent E. coli cells, protein expression will be induced using IPTG, in 
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the same way that previous work did with the in vitro fusion protein. Whole-cell, in vivo 
fluorescence studies will be performed in the presence of ampicillin. The data gathered should be 
similar to the data gathered in the in vitro studies; a decrease in fluorescence over time. The 
expected difference in the in vitro and in vivo data is that the in vivo data will contain a lag before 
the decrease in fluorescence is observed since the antibiotic must cross the cell membrane – thus 
allowing for bioavailability studies. 
For the in vivo portion of the project, it was not necessary to have a FLAG affinity tag to 
aid in purifying the protein from cellular material, because the fluorescence studies will be 
performed in vivo. The protein will remain in the cell and its antibiotic-resistant/fluorescence 
activity will be directly observed. The in vivo fusion protein will have the potential to be used in 
whole-cell bioavailability assays, indirectly measuring the activity of β-lactamase in response to 
treatment with β-lactam antibiotics, as well as studying inhibitors, by observing the change in 
fluorescence of the EGFP domain of the protein. 
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Methods and Materials 
Apparati 
 Bacterial overnight cultures were prepared on a VWR shaker table and incubator 
(Cornelius, OR). Polymerase chain reaction (PCR) was performed in an Eppendorf Mastercycler 
Personal Thermocycler (Hamburg, Germany). PCR optimization was performed in an Applied 
Biosystems Veriti 96 Well Plate Thermal Cycler from ThermoFisher Scientific (Asheville, NC).  
Gel electrophoresis was run in an IBI Quickscreen QS-710 (New Haven, CT) connected to a 
Thermo EC105 power supply (Asheville, NC). Gels were visualized using a VWR UVP UV 
transilluminator (Cornelius, OR). Enzyme digestions were performed in a VWR 1208 water bath 
(Cornelius, OR). Bacterial plates were grown in a VWR Shel Lab 1500E incubator (Cornelius, 
OR). Concentrations were determined using a ThermoScientific NanoDrop 2000C 
Spectrophotometer (Asheville, NC). Also used throughout the experiment were a Tuttnauer 
3870ELV autoclave (Shemesh, Israel), an Eppendorf 5424C centrifuge (Westbury, NY), a Mettler 
Toledo AL 54 analytical balance (Columbus, OH), and a ThermoScientific -80°C freezer 
(Asheville, NC). In addition to the instruments, Eppendorf 1.5 mL microcentrifuge tubes 
(Westbury, NY), Fisher Scientific Fisherbrand petri dishes (Pittsburgh, PA) and 14 mL Becton 
Dickinson Falcon tubes (Franklin Lakes, NJ) were also used. 
Reagents: 
 Luria Bertani (LB) broth and LB agar were purchased from Difco (Lawrence, KS). PCR 
MasterMix was purchased from ThermoScientific (Asheville, NC). HindIII, EcoRI, digestion 
buffer H, digestion buffer M, loading dye, DH5α cells, pUC19 DNA, SOC media, DNA ligase, 
ligase buffer, agarose, and DNA ladder were purchased from Invitrogen (Carlsbad, LA). 
RedSafeTM nucleic acid staining solution was purchased from VWR (Cornelius, OR). Ethidium 
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bromide, ampicillin sodium salt, and kanamycin sulfate were purchased from Sigma Aldrich (St. 
Louis, MO). Primers were ordered from Eurofins MWG Operon (Huntsville, AL). The pEGFP 
vector was purchased from Clontech (Mountain View, CA), the pFLAG-MAC vector was 
purchased from IBI Kodak (New Haven, CT), and the pET28b vector was donated by Ece Karatan 
(Appalachian State University). Tris-acetate-ethylenediaminetetraacetic acid buffer (TAE buffer) 
(made one liter at 25x concentration, then diluted to 1x with DI water) was mixed in house with 
tris base (121.0 g) and glacial acetic acid (28.6 mL) from EM Science (Gibbstown, NJ) as well as 
EDTA (18.6 g Na2EDTA) from EMD Chemicals (Gibbstown, NJ). Miniprep, gel extraction, and 
PCR purification kits were purchased from Qiagen (Valencia, CA). Sterile techniques were used. 
LB Broth and Agar Plates: 
 LB broth was prepared by adding 8 g of LB broth powder to 400 mL of DI water in a glass 
storage bottle. The broth solution was autoclaved. After autoclaving, 20 mg of kanamycin sulfate 
was added for a concentration of 50 μg/mL for LB-kan. For LB-amp, 40 mg of ampicillin sodium 
salt was added for a concentration of 100 μg/mL.  
LB plates were prepared by adding 14 g of LB agar powder to 400 mL of DI water in a 
glass storage bottle. The agar solution was autoclaved and left to cool to less than 50°C. After 
cooling, 20 mg of kanamycin sulfate was added for a concentration of 50 μg/mL for the plates for 
pET28b colonies. For plates for pEGFP colonies, 40 mg of ampicillin sodium salt was added for 
a concentration of 100 μg/mL. The agar solution was poured into petri dishes to about two-thirds 
full, allowed to cool and solidify, and stored upside down in the refrigerator. 
Bacterial Cultures and MiniPrep: 
 Bacterial cultures of pEGFP were prepared and grown by adding a toothpick scraped across 
E. coli transformed with the source DNA from stock culture from the -80°C freezer. Bacterial 
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cultures of pET28b were prepared and grown by adding a toothpick scraped across the source 
DNA from plates of pET28b and pEGFP to a 15-mL Falcon tube with 3 mL of LB-kanamycin 
broth for pET28b or LB-ampicillin broth for pEGFP. The cultures were incubated for 16 hours 
overnight on the shaker table at 37°C and 200 rpm. 
 The DNA was isolated from the bacterial cells using the QIAprep Spin Miniprep Kit 
according to the Qiagen protocol. First, the bacterial cultures were transferred into a 1.5-mL 
Eppendorf microcentrifuge tube, centrifuged at 13,000 rpm for 1 minute, and decanted until only 
the pellet remained. This was performed for each bacterial culture until none remained in the 
Falcon tube. The remaining pellet was resuspended in 250 μL of Buffer P1 by vortexing. Once the 
pellet was resuspended 250 μL of Buffer P2 were added and the mixture was inverted 6 times. 
Then, 350 μL of Buffer N3 were added and the mixture was inverted 6 times again. The tube was 
centrifuged at 13,000 rpm for 10 minutes. After centrifugation the supernatant was transferred into 
a QIAprep spin column and centrifuged at 13,000 rpm for 1 minute. The flow-through was 
discarded. The spin column was washed with 750 μL of Buffer PE and centrifuged at 13,000 rpm 
for 1 minute. The spin column was removed from the tube, the bottom of the column was wiped 
with a Kimwipe. To elute the DNA from the column 30 μL of Buffer EB were added and left to 
sit for 1 minute. The column was centrifuged at 13,000 rpm for 1 minute. The spin column was 
discarded and the flow-through containing the isolated DNA was stored in the 4°C refrigerator for 
later use. 
Polymerase Chain Reaction and Gel Electrophoresis 
 After isolation of plasmids using MiniPrep, the genes for EGFP and β-lactamase each had 
to be isolated from the pEGFP plasmid and amplified using polymerase chain reactions (PCR). 
The PCR reaction mixtures contained 21 µL of sterile water, 2 µL of DNA, 1 µL of reverse primer, 
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1 µL of forward primer, and 25 µL of PCR MasterMix. Table 1 below depicts the primers used for 
the individual gene isolation in the validation of the pH theory portion of the project. 
Table 1. Primers used in PCR mixture for individual gene isolation in the validation of the pH 
theory portion of the project 
β-lactamase 
Forward Primer 
5’ - ACCATCGCAGTAAAGCTTCAC 
CCAGAAACGCTGGTGAAAGTA - 3’ 
Reverse Primer 
5’ - ACCGCCGCAGTGAATTCATTA 
CCAATGCTTAATCAGTGAGGC - 3’ 
EGFP 
Forward Primer 
5’ - ACCTACGCAGTTAAGCTTGT 
GAGCAAGGGCGAGGAGCTG - 3’ 
Reverse Primer 
5’ - TACACCGCAGTGAATTCAT 
TACTTGTACAGCTCGTCCAT - 3’ 
 
 The underlined sequence of each primer is the recognition sequence for the restriction 
enzymes. Both forward primers contain the sequence for HindIII and both reverse primers 
contained the sequence for EcoRI. These restriction sites were chosen, because they are unique to 
the MCS of the pFLAG-MAC vector. Table 2 below depicts the PCR program parameters. 
Table 2. PCR parameters for gene isolation from pEGFP 
Stage Temperature Time 
Denaturing 94°C 1 Minute 
Annealing 50°C 1 Minute 
Extending 72°C 2 Minutes 
Number of Cycles 50 
 
 After PCR, the DNA was separated using gel electrophoresis. The gel was made by 
dissolving 0.5 g agarose in 50 mL 1x TAE buffer. The 1x TAE buffer was made by diluting 40 
mL 25x TAE buffer (121.0 g Tris base, 28.6 mL glacial acetic acid, and 18.6 g Na2EDTA, diluted 
to 1 L with deionized water (DI)) to 1 L. To the solution, 2 μL of RedSafeTM nucleic acid staining 
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solution, or 3 μL of ethidium bromide, were added. The solution was poured into a gel casting tray 
and allowed to cool. After the gel solidified, the products from the PCR were mixed with 5 μL 
loading buffer and placed in the wells of the gel in 25 μL aliquots. Five microliters of 1 kb ladder 
was added to a single well to use as a reference. The gel was run in 1x TAE buffer at 100 V for 40 
minutes. When finished running, the gel was transferred to a UV transilluminator to view the 
bands. Both EGFP and β-lactamase bands appear around 800 base pairs. The desired bands were 
excised, placed in 1.5 mL Eppendorf tubes, and stored in the refrigerator for DNA extraction from 
the gel. 
 In order to extract the DNA from the gel, the bands were processed using a gel extraction 
kit from Qiagen. First, Buffer QG was added at a ratio of 3:1 buffer to gel volume. The tube was 
held in hand until the gel melted, with intermittent vortexing. The solution was transferred to a 
spin column and centrifuged at 13,000 rpm for 1 minute, with the flow-through being discarded. 
The spin column was washed with 750 μL Buffer PE and centrifuged at 13,000 rpm for 1 minute 
twice, discarding the flow-through each time. The outside of the column was wiped with a 
Kimwipe. The column was placed in a 1.5 mL Eppendorf tube and 30 μL Buffer EB was added to 
the center of the column. It was left to sit for 1 minute, then centrifuged at 13,000 rpm for 1 minute. 
The spin column was discarded and the flow-through was stored in the refrigerator for later use. 
 When PCR was performed for the fusion proteins, the procedure was slightly different. 
Two PCR programs were run separately. In each run, the contents remained much the same as the 
PCR for the individual genes, but different primers were used. The first PCR program used the 
same parameters as the PCR for individual genes, with the only difference being the primers. Table 
3 depicts the primers used for the in vitro fusion protein PCR. Table 4 depicts the primers used for 
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the in vivo fusion protein PCR. The different primers included an overlap section later used to fuse 
the genes together. The restriction sites are underlined, and the spacer region is italicized. 
Table 3. Primers used in PCR mixture for recreation of in vitro fusion protein 
EGFP 
Forward Primer 
5’-ACCACCGCAGTAAAGCTTATG 
GTGAGCAAGGGCGAGGAG-3’ 
Reverse Overlap 
Primer 
5’-TCCTCCTCCTCCCTTGTA 
CAGCTCGTCCATGCC-3’ 
β-lactamase 
Forward Overlap 
Primer 
5’-ATGGACGAGCTGTACAAGGGAGGA 
GGAGGACACCCAGAAACGCTGGTGAAA-3’ 
Reverse Primer 
5’-ACCGCCGCAGTAGAATTCTTA 
CCAATGCTTAATCAGTGAGGC-3’ 
 
Table 4. Primers used in PCR mixture for creation of in vivo fusion protein 
β-lactamase 
Forward Primer 
Fusion Step 1 
5’ - TTATTATTATTAATGAGTA 
TTCAACATTTCCGTGTCGCC - 3’ 
Forward Primer 
Fusion Step 2 
5’ - ACCACCGCAGTAAAGCTT 
ATGAGTATTCAACATTTCCGT-3’ 
Reverse Overlap 
Primer 
5’-TCCTCCTCCTCCCCAATG 
CTTAATCAGTGAGGC-3’ 
EGFP 
Forward Overlap 
Primer 
5’-TCACTGATTAAGCATTGGGGAGGA 
GGAGGAATGGTGAGCAAGGGCGAGGAG-3’ 
Reverse Primer 
Fusion Step 1 
5’ - AGGAGGAGGAGGTTACTTG 
TACAGCTCGTCCATGCCGAG - 3’ 
Reverse Primer 
Fusion Step 2 
5’-ACCGCCGCAGTACTCGAGTTA 
CTTGTACAGCTCGTCCATGCC-3’ 
 
 After the first round of PCR was completed, the bands for β-lactamase and EGFP were 
extracted together in the same tube in order to create a mixture of the DNA for both genes. The 
mixture was used in the second round of PCR. The primers used in the second round of PCR did 
not include the overlap primers, only the β-lactamase forward fusion Step 2 primer and EGFP 
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reverse fusion Step 2 primer were used. Figure 21 below depicts the fusion Step 1 and Step 2 
overlap amplifications.  
  
 
Figure 21. Illustration of steps one and two of fusion overlap PCR 
 41 
The parameters for the PCR program were different, with two sets of conditions being 
used. Table 5 below depicts the PCR program parameters. Due to the larger size of just over 1500 
bp for the fusion gene the extension time was increased. After the second round of PCR, another 
gel was run, and the bands were extracted using the above protocol for gel extraction. 
Table 5. PCR parameters used for overlap extension PCR for in vitro and in vivo fusion genes 
Stage Temperature Time 
Denaturing 94°C 1 Minute 
Annealing 45°C 1 Minute 
Extending 72°C 3.5 Minutes 
Number of Cycles 20 
Denaturing  94°C 1 Minute 
Annealing 50°C 1 Minute 
Extending 72°C 3.5 Minutes 
Number of Cycles 30 
 
Enzyme Digestion and Purification 
 After the DNA was removed from the gel, the next step was to use a specific restriction 
endonuclease to create sticky ends. Both the EGFP and β-lactamase genes were digested, as well 
as the pFLAG-MAC vector. Digestion of the vector was necessary so that the genes could be 
inserted into it. Digestions were performed sequentially, using HindIII then EcoRI, or concurrently 
using both HindIII and EcoRI. HindIII and XhoI was used for the in vivo fusion protein. The 
reaction mixture for each of the enzymes contained 25.5 μL DNA, 3 μL enzyme buffer, and 1.5 
μL restriction enzyme. Each digestion was left in the water bath at 37°C for 3 hours. Once 
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FastDigestTM enzymes were obtained, the digestion was left in the water bath at 37oC for 15 
minutes. 
 After the 3 hours or 15 minutes, the first digestion was stopped by PCR purification. The 
purification was completed using a Qiagen QIAquick PCR Purification kit as follows. Five 
volumes of Buffer PB were added to 1 volume of digested product and mixed. The DNA was 
bound by centrifuging at 13,000 rpm for 1 minute with the flow-through being discarded. The 
solution was washed with 750 μL Buffer PE and centrifuged twice at 13,000 rpm for 1 minute, 
with flow-through being discarded. The column was placed in a 1.5 mL Eppendorf tube, and the 
DNA was eluted by adding 30 μL Buffer EB to the center of the column and letting it sit for 1 
minute. It was then centrifuged at 13,000 rpm for 1 minute. After the EcoRI digestion was 
completed, the contents of the tube were run on a gel, the desired bands were excised, and the 
DNA was extracted using the above protocol. After completion of both digestions, the products 
were stored in the refrigerator for later use. 
Nanodrop 
 The concentration of both the gene inserts and vector were determined using the 
NanoDrop. The instrument was first cleaned by adding 3 μL of sterile water to the pedestal. After 
2 minutes, the pedestal was dried by dabbing with a Kimwipe. Two microliters of elution buffer 
were placed on the pedestal to blank the instrument. Samples were then added to the pedestal in 2 
μL aliquots with the elution buffer being ran in between each sample to reblank the instrument. 
After samples were run, the pedestal was again cleaned with 3 μL of sterile water and dabbed dry 
with a Kimwipe. 
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Ligation and Transformation 
 The concentrations determined from the NanoDrop were used to determine the appropriate 
volumes to be used in the ligation. Equation 1 depicts the formula used for the calculation. The 
solution of the equation was then divided by the concentration of the insert. The equation had 3 
constants, the kilobasepairs of the insert (0.8), the kilobasepairs o the vector (5), and the ratio of 
the insert to the vector (3). The destination vector used for the validation of the pH theory and in 
vitro assay portions of the project was pFLAG-MAC. The destination vector used for the in vivo 
assay portion of the project was pET28b. For the ligation, 2 μL of T4 DNA ligase, 4 μL ligase 
buffer, and the determined amounts of insert and vector, forming a 3:1 insert:vector ratio, were 
used. Water was added to the mixture to bring it to a volume of 20 μL. The ligation was completed 
by holding the mixture at 16°C for at least 12 hours overnight. 
 
Equation 1. Ligation calculation using Nanodrop concentration results 
nanograms of vector × kilobasepairs of insert (0.8) × ratio of insert to vector (3) 
kilobasepairs of vector (5)  = µL of insert added 
   
Transformations were performed to acquire plated colonies expressing the pET28b vector 
and pEGFP source plasmid. Transformations were also performed for the individual gene 
expression with pLP003 and pLP004 plasmids. First, 2.5 μL of plasmid were transferred into 25 
μL of DH5α competent cells in Falcon tubes. The contents were incubated on ice for 15 minutes, 
heat shocked in a 42°C water bath for 45 seconds and incubated on ice again for 2 minutes. After 
the second incubation on ice, 350 μL of SOC media was added to the plasmid and cell mixture. It 
was then placed on the shaker table at 37°C and 200 rpm for 45 minutes. After the incubation in 
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the shaker table, 10 μL and 20 μL aliquots of the mixture were spread on agar plates with the 
appropriate antibiotic and incubated for 24-48 hours at 37°C. 
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Results and Discussion 
Recreation of the In Vitro Fusion Protein 
 For the recreation of the in vitro fusion protein, the genes for β-lactamase and EGFP were 
successfully isolated with the gene spacer attached. Figure 22 below depicts the gel image 
following amplification of the individual genes with the primers for the in vitro fusion protein. The 
high background observed is likely indicative of the staining dye binding to the gel matrix, the gel 
being contaminated with DNA, or the electrophoresis chambers needing cleaning to remove 
contaminants. 
 
 
Figure 22. InvitrogenTM DNA size ladder and gel image of amplified β-lactamase and EGFP with 
spacer attached using in vitro fusion protein primers 
 
 After isolation and amplification of the individual genes, fusion PCR was performed but 
the two individual genes could not be fused together into one as no bands of the appropriate size 
were observed in the gel image following overlap PCR. More work needs to be done to recreate 
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the fusion gene. Although it has been accomplished in the past, the results have not been replicated. 
Adjustments involving new polymerases and PCR conditions will be looked at in order to create 
the in vitro fusion protein, as Pfu polymerase was used in the previous creation of the in vitro 
fusion protein. 
Validation of the pH Theory 
 PCR optimization was performed to determine the ideal annealing temperatures of the 
primers used for the isolation of the β-lactamase and EGFP genes. Gradient PCR was performed 
with an annealing temperature range of 50OC to 70OC, in increments of 4OC. Figures 23 and 24 
below depict the gel images obtained from gel electrophoresis following gradient PCR. The gel 
images show that the optimum annealing temperature for both the β-lactamase and EGFP primers 
is 50OC, as it produced the most intense bands. This temperature was used as the annealing 
temperature in subsequent PCR amplifications of the individual genes. At the bottom end of each 
lane are primer dimers, by-products of PCR in which the primer molecules hybridized. 
 
Figure 23. Gel image of   Figure 24. Gel image of EGFP after                                             
β-lactamase after PCR annealing     PCR annealing optimization 
optimization   
Lane A: 50OC 
Lane B: 54OC 
Lane C: 58OC 
Lane D: InvitrogenTM 1 Kb 
Plus DNA Ladder 
Lane E: 62OC 
Lane F: 66OC 
Lane G: 70OC 
A B C D E F G A B C D E F G 
650 bp 850 bp 
650 bp 850 bp 
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In the validation of the pH theory assay, the genes for both β-lactamase and EGFP were 
successfully isolated from the pEGFP plasmid and amplified via PCR. Figure 25 below depicts 
the gel image obtained from gel electrophoresis following PCR. The bands for β-lactamase and 
EGFP fall between the 650 and 850 bp ladder bands, the appropriate locations for the two genes; 
β-lactamase and EGFP have gene sizes of 789 bp and 714 bp, respectively. The DNA was isolated 
by gel extractions performed on excised gel samples.  
 
Figure 25. Gel image of amplified β-lactamase and EGFP obtained following PCR 
 
 After the bands were excised and the DNA was extracted, the concentrations of the 
amplified DNA were determined using the NanoDrop instrument prior to digesting with restriction 
enzymes. After digestions, the concentrations were again determined. This was performed to get 
concentrations for the calculations required for the ligation of the genes into the pFLAG-MAC 
vector. However, after performing ligation and transformation of the genes, no colony growth 
occurred. A positive control of pUC19 DNA had been transformed as well, and growth occurred 
A B C D F E G 
Lane A: β-lactamase Gene 
Lane B: β-lactamase Gene 
Lane C: EGFP Gene 
Lane D: EGFP Gene 
Lane E: InvitrogenTM 1 Kb 
Plus DNA Ladder 
Lane F: EGFP Gene 
Lane G: EGFP Gene 
650 bp 850 bp 
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for the pUC19 colonies. This indicated that the error had occurred during the ligation and not the 
transformation. Initially, the gel extraction procedure was very inefficient; large amounts of DNA 
were lost through the process, resulting in percent yields of DNA at less than 20% from gel 
extractions following digestion. The process went through significant testing to optimize it and 
reduce the DNA loss. The EGFP gene was used as the DNA sample for each scenario. Several 
variables were altered in the protocol to determine the ideal process for the greatest DNA recovery. 
To optimize the process, four variables were altered: 1) the number of times the dissolved gel 
sample was run through the column, 2) the binding speed at which the column was centrifuged to 
bind the DNA, 3) the number of times the bound sample was washed with PE buffer, and 4) the 
amount of time the sample was let stand with EB buffer for elution. Table 6 below depicts the 
results of the optimization process, with the concentrations of the samples before and digestion 
with EcoRI and HindIII restriction enzymes. Based on the percent recoveries of each scenario, the 
best combination was determined to be running the dissolved gel through the column two times, 
binding the DNA at 7,000 rpm, washing the bound sample one time with PE buffer, and letting the 
sample stand with elution buffer for three minutes before centrifugation.  
Table 6. EGFP DNA concentrations before and after digestion for the optimization of the gel 
extraction protocol 
Variable Conc. Before Dig. Conc. After Dig. % Recovery 
1) 1 Time 81.4 ng/µL 14.0 ng/µL 17.2% 
1) 2 Times 72.4 ng/µL 43.0 ng/µL 59.4% 
1) 3 Times 77.8 ng/µL 47.2 ng/µL 60.7% 
2) 2,000 rpm 93.1 ng/µL 69.7 ng/µL 74.9% 
2) 7,000 rpm 87.9 ng/µL 68.8 ng/µL 78.3% 
2) 13,000 rpm 69.8 ng/µL 10.7 ng/µL 15.3% 
3) 1 Wash 83.4 ng/µL 17.8 ng/µL 21.4% 
3) 2 Washes 73.5 ng/µL 13.3 ng/µL 18.1% 
3) 3 Washes 76.1 ng/µL 14.9 ng/µL 19.6% 
4) 1 Minute 71.7 ng/µL 14.2 ng/µL 19.8% 
4) 3 Minutes 78.2 ng/µL 52.6 ng/µL 67.3% 
4) 6 Minutes 84.8 ng/µL 56.4 ng/µL 66.5% 
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The optimum combination of variables described above was used in gel extractions, 
yielding consistent percent recoveries of over 80%. Table 7 below depicts the concentrations of β-
lactamase and EGFP extracted from the gel in Figure 25 above, in addition to the pFLAG-MAC 
vector, before and after digestion using the optimized gel extraction protocol. 
Table 7. DNA concentrations before and after digestion of DNA with EcoRI and HindIII 
restriction enzymes, and percent recovery 
Gene Conc. Before Dig. Conc. After Dig. % Recovery 
β-lactamase (1) 78.7 ng/µL 67.2 ng/µL 85.4% 
β-lactamase (2) 83.1 ng/µL 71.4 ng/µL 85.9% 
EGFP (1) 63.8 ng/µL 52.7 ng/µL 82.6% 
EGFP (2) 71.1 ng/µL 62.1 ng/µL 87.3% 
EGFP (3) 78.4 ng/µL 64.9 ng/µL 82.8% 
EGFP (4) 80.3 ng/µL 71.2 ng/µL 88.7% 
pFLAG-MAC 124.8 ng/µL 107.5 ng/µL 86.1% 
 
After digestions, the determined concentrations of extracted DNA were used to calculate 
the volume of DNA solution to add to the ligation solution. This is as far as the ‘validation of pH 
theory’ portion of the project went. After ligations were performed, the resulting recombinant 
plasmids were transformed into DH5α cells. Either the ligation or transformation proved to be 
unsuccessful each time as no growth occurred on agar plates following transformation. It is likely 
that it was the ligations that proved to be unsuccessful as transformations using the pEGFP vector 
plasmid (which contains both β-lactamase and EGFP genes) were successful, as were 
transformations performed using pUC19 DNA as a positive control. 
Development of the In Vivo Fusion Protein 
 Unlike the in vitro portion of the project, the in vivo portion relies an alternative antibiotic 
resistance other than ampicillin resistance, as ampicillin resistance is being conferred by 
transforming E. coli cells with a plasmid containing the fusion gene of β-lactamase and EGFP. 
Due to this, pFLAG-MAC could not be used as the expression vector. Instead, pET28b, a plasmid 
vector containing the gene for kanamycin resistance is being used. Frozen stocks of pET28b were 
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used to create overnight cultures to be miniprepped. Using the miniprepped pET28b DNA, 
transformations were performed to maintain a supply of vector plasmid DNA. Using the resulting 
cultures, minipreps were created to be used in ligations with the in vivo fusion protein. 
 Initially, the primer set of in vivo primers had been incorrectly designed and were not 
appropriate for this experiment. The primers contained restriction sites for HindIII and EcoRI and 
were placed in the wrong orientation for ligation of the desired recombinant gene into the pET28b 
vector plasmid; the EGFP gene would be ligated in upstream of β-lactamase and would have been 
transcribed first, negating the goal of the in vivo portion of the project. In addition, the position of 
the restriction sites would have caused a frame-shift mutation when the construct was translated. 
Therefore, even if the fusion gene had been constructed, it would not have been ligated into the 
vector or transcribed by the bacteria. Table 8 below depicts the incorrectly designed primers. The 
restriction sites are underlined. Figures 26 and 27 below depicts the gel image resulting from the 
first and second fusion PCR procedure using the incorrectly designed primers. 
Table 8. Incorrectly designed primers for in vivo fusion gene 
β-lactamase Forward with 
HindIII 
5’ – ACCACCTACTTAAGCTTAAT 
GAGTATTCAACATTTCCGT – 3’ 
EGFP Reverse with EcoRI 5’ – ACCACCTACTGAATTCATT 
TACTTGTACAGCTCGTCCAT – 3’ 
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Figure 26. Gel image of                    Figure 27. Gel image of unsuccessful 
individually amplified genes using   overlap PCR extension using 
incorrectly designed primers             incorrectly designed primers 
 
New primers were used containing the correct restriction sites – HindIII and XhoI – and 
additional tails off the 5’ ends of the β-lactamase forward primer and EGFP reverse primer. Adding 
the tail should increase the likelihood of the primers in the second PCR procedure binding and 
allow a more successful fusion. Table 9 below gives the sequence of the new primers with the tail 
added italicized. After the primers were ordered and arrived, they were resuspended in TE buffer, 
pH 7.4. 
Table 9. New primers used in the first in vivo PCR procedure 
β-lactamase 
Forward 5’ - TTATTATTATTAATGAGTATTCAACATTTCCGTGTCGCC - 3’ 
EGFP Reverse 5’ - AGGAGGAGGAGGTTACTTGTACAGCTCGTCCATGCCGAG - 3’ 
 
 Using the above primers, and two overlap primers for β-lactamase and EGFP, the genes 
were individually isolated and amplified with the 5’ tails and 3’ gene spacer attached. Figure 28 
below depicts the gel image following amplification of the individual genes with the primers for 
the in vivo fusion protein. 
A B C 
Left Gel Image 
Lane A: EGFP 
Lane B: InvitrogenTM 1 Kb 
Plus DNA Ladder 
Lane C: β-lactamase 
Right Gel Image 
Lane A: EGFP 
Lane B: InvitrogenTM 1 Kb 
Plus DNA Ladder 
Lane C: β-lactamase 
A B C 
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Figure 28. Gel image of amplified β-lactamase and EGFP with tail and spacer attached using in 
vivo fusion protein primers 
 
After isolation and amplification of the individual genes, fusion PCR was performed but 
the two individual genes were not be fused together into one. A PCR protocol that had not been 
optimized was utilized for the in vivo construct. As such, alterations to the conditions in which 
PCR is performed will be looked into, including the polymerase used, the reaction 
temperature/time conditions, and the solution in which the reaction takes place so that the process 
can be optimized. Figure 29 below depicts the gel image obtained in the gradient PCR for the 
fusion PCR procedure. The reaction was unsuccessful, indicating that some parameters, likely 
other than annealing temperature of the primers, must be altered and observed. The gradient 
reaction run below was run with an annealing temperature range of 45OC to 65OC, in increments 
of 4OC. At the bottom end of the gel, primer dimers can be observed. 
A B C D E F 
Lane A: β-lactamase Gene with Tail and Spacer 
Lane B: β-lactamase Gene with Tail and Spacer 
Lane C: InvitrogenTM 1 Kb Plus DNA Ladder 
Lane D: EGFP Gene with Tail and Spacer 
Lane E: EGFP Gene with Tail and Spacer 
Lane F: EGFP Gene with Tail and Spacer 
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Figure 29. Gel image of gradient fusion PCR products for optimal annealing temperature of 
primers 
 
  
 
 
 
 
 
 
 
 
 
 
A B C D F E G 
Lane A: 45OC 
Lane B: 49OC 
Lane C: 53OC 
Lane D: InvitrogenTM 1 Kb 
Plus DNA Ladder 
Lane E: 57OC 
Lane F: 61OC 
Lane G: 65OC 
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Conclusions and Future Work 
 The individual genes for β-lactamase and EGFP were successfully isolated from the 
plasmid pEGFP and amplified via PCR with primers containing the restriction site sequences for 
HindIII and EcoRI restriction enzymes. The genes were digested using the restriction enzymes and 
yielded suitable DNA concentrations for ligation into a vector plasmid. However, after ligation 
and transformation, no colony growth was observed for the β-lactamase and EGFP transformed 
bacteria. Error occurred during ligation of the digested genes into the pFLAG-MAC vector as a 
positive control of pUC19 DNA during transformation resulted in bacterial growth on selective 
media. Initially, low concentrations following gel extraction were the cause of unsuccessful 
ligations. After gel extraction optimization, the likely error is impurities, such as agarose, in the 
extracted DNA. β-lactamase and EGFP must still be successfully ligated into the pFLAG-MAC 
expression vector and transformed into DH5α cells for the validation of the pH theory. 
 The genes for β-lactamase and EGFP, after being isolated, were successfully amplified via 
PCR in the first step of fusion PCR for the recreation of the in vitro fusion protein using the in 
vitro primers, having the spacer attached. However, the overlap step of fusion PCR was not 
successful, so the in vitro fusion gene must still be recreated. The in vitro fusion gene will be 
digested with HindIII and EcoRI restriction enzymes and ligated into pFLAG-MAC for 
expression, and the protein will be used for comparison in fluorescence measurements. The 
isolated β-lactamase and EGFP were successfully amplified via PCR in the first fusion PCR for 
the creation of the in vivo fusion protein using the newly designed in vivo primers, having the 
spacer and tail attached. However, the overlap second step of fusion PCR was not successful, so 
the in vivo fusion gene must still be created. The in vivo fusion gene will be digested with XhoI 
and HindIII restriction enzymes and ligated into pET28b for expression. 
 55 
 In order to improve the experimental design and increase the success of the project in the 
future, alternative protocols should be considered. The primary issue in this research is the fusion 
of the β-lactamase and EGFP genes into a single fusion construct. Currently, the genes are being 
fused via overlap extension PCR using Taq polymerase. Literature searches reveal that Taq 
polymerase is a cheaper, useful polymerase for the amplification of individual products, but is an 
inefficient enzyme for the construction of fusion products. Taq polymerase lacks 3’ to 5’ 
exonuclease proofreading activity. Not only does this inhibit the fidelity of the enzyme, it also 
limits the size of the amplicon as well. Taq has been demonstrated to sometimes be unable to 
amplify DNA sequences in the size range of 1500 to 2000 bp.51 The fusion product of β-lactamase 
and EGFP is just over 1500 bp. In addition, Taq leaves single A-overhangs at the 3’ ends of DNA 
sequences, disrupting overlapping regions during the overlap extension fusion PCR.52 Taq’s 
inability to efficiently fuse together gene products highlights a flaw in the experimental design. As 
such, future research should be performed using high-fidelity enzymes capable of efficiently 
generating larger constructs. Experimentation performed by Puckett et. al. using Pfu polymerase 
yielded a fusion protein to be used for in vitro fluorescence studies.50 Pfu and Pfu Turbo are high-
fidelity DNA polymerases with 3’ to 5’ exonuclease activity used during PCR for the generation 
of larger amplicons with fewer base-substitution errors. Pfu has been used in fusion PCR to 
generate products up to 20 kb in size, and up to 35 kb fragments in non-fusion amplification.51,53 
A limitation of Pfu is that it is slower than Taq, requiring longer elongation cycles, up to twice as 
long, to amplify the DNA.54 To overcome the reduced accuracy and fidelity of Taq and the 
increased elongation times of Pfu,  mixtures of Taq and Pfu acting synergistically have been used, 
taking advantage of Taq’s speed and Pfu’s proofreading.51,55,56 Taq PLUS DNA Polymerase is a 
polymerase mixture that contains both Taq and Pfu. Taq PLUS has an error rate of 7.5x10-5 per 
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nucleotide per cycle. Taq has an error rate of 1.5x10-4 per nucleotide per cycle, while Pfu has an 
error rate of 5.1x10-6 per nucleotide per cycle.57,58 The error rates indicate that by mixing the Taq 
and Pfu polymerase, the error decreases from that of Taq alone, but is still greater than that of Pfu 
alone. Taq was being used in a MasterMix to reduce error in the PCR steps of the experiment. It 
is recommended to use Pfu over Taq or a mixture, as Pfu has been demonstrated to be effective 
for fusing β-lactamase and EGFP, and the increased time of PCR is a small price to pay for 
increased success. Another polymerase for consideration is Phusion, a high-fidelity, high-
processivity polymerase. Phusion polymerase has a novel Pyrococcus-like 3’ to 5’ exonuclease 
proofreading domain fused to a protein DNA-binding domain, allowing it to ‘clamp’ on to DNA 
and stay attached over long strands of DNA to be amplified for increased processivity. Phusion, 
like Pfu, has 3’ to 5’ exonuclease activity to improve fidelity. Phusion has an error rate of       
3.9x10-6 per nucleotide per cycle, comparable to that of Pfu.57 Phusion has been demonstrated to 
be effective in overlap extension PCR repeatedly, making it a prime candidate as the PCR 
polymerase to be used for future work on this experiment.59, 60,61 Both Pfu and Phusion have been 
demonstrated as high-fidelity enzymes and have a high efficacy for overlap extension PCR. 
However, Phusion has a greater processivity than Pfu, making Phusion the better candidate as it 
will have comparable fidelity with increased processivity, reducing times required for PCR. 
Similar to Phusion, Q5 polymerase from New England Biolabs could be considered. Like Phusion, 
Q5 polymerase has a higher fidelity than Taq and is faster than Pfu. In addition, it can come in a 
mastermix, like Taq, keeping with the goal of reducing human error during preparation of PCR 
reaction mixtures.62 
 Another issue encountered, though less major, was the presence of primer dimers following 
PCR. Primer dimers form as a PCR byproduct when the primer molecules hybridize to each other 
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due to complementary bases in the primer sequences. When primer dimers form, they reduce PCR 
efficiency by competing for resources needed for amplification of target DNA and increasing non-
target products of PCR.63 The simplest method to reduce their formation is the optimization of the 
annealing temperature via gradient PCR. Though this has been performed for the individual genes 
and primers, it should be performed again with new polymerases, and for the validation of the 
optimal annealing temperatures of the current primers, and for the determination of the optimum 
annealing temperature for the overlap primers. The addition of dimethyl sulfoxide (DMSO) is also 
a possible solution. DMSO optimizes the specificity of product formation in PCR, inhibiting the 
formation of secondary DNA structures and binding to DNA to prevent the reannealing of single-
stranded DNA. DMSO is also known to facilitate the annealing of primers with template DNA, 
increasing target product formation in PCR. A 5% DMSO solution has been determined to be 
optimal.64 
In addition to running traditional PCR, real time, or quantitative PCR (qPCR) needs to be 
run to observe the DNA amplification process as it is happening. qPCR uses dye-based fluorescent 
labeling to accomplish this, taking fluorescence measurements during each cycle as the DNA is 
amplified. This allows the observance of when the DNA begins to amplify logarithmically and 
allows the quantification of the amount of DNA present. By running qPCR, it will be possible to 
observe at what stage the DNA begins to amplify logarithmically.65 When experimenting with the 
various polymerases, qPCR and PCR optimization procedures will have to be performed 
extensively to determine the optimal conditions for the various polymerases to get ideal amplicon 
yield and results. Figure 30 below depicts a diagram of qPCR, where Cq is the cycle at which 
logarithmic amplification begins. 
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Figure 30. Diagram of qPCR.66 
 
An alternative method for construction of the fusion protein is to use expressed protein 
ligation. EPL is a post-translational modification method in which the C-terminus of a protein is 
modified to contain a thioester, while the N-terminus of another is modified to contain a cysteine 
residue, allowing the conjugation of the proteins by the formation of a native peptide bond between 
the two modifications.67 EPL has been used for the preparation of fusion proteins. Yu et. al. used 
EPL to synthesize a fusion construct of EGFP and synthetic cell penetrating peptide. The EGFP 
thioester was prepared by intein-mediated purification with an affinity chitin-binding tag 
(IMPACT) system, used to generate an EGFP-intein-chitin binding domain (EGFP-I-CBD) 
protein, which then allowed for on-column cleavage of purified EGFP-I-CBD to generate the 
EGFP thioester. The EGFP thioester was incubated in ligation buffer with the synthesized cell 
penetrating peptide, resulting in a fusion protein of the two.68 A vital limitation of this technique 
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is that it is a post-translation modification. Currently, performing the in vivo portion of this research 
would be very difficult using EPL, but research into such protocols is ongoing. Hauser and Ryan 
performed EPL using an N-terminal cysteine containing fragment that was generated in vivo using 
a pelB fusion protein. They subjected a recombinant fusion protein comprised of the N-terminal 
residues 1-111 of apolipoprotein E, intein, and CBD to 2-mercaptoethanesulfonic acid to cleave 
it. A second fusion protein of a pelB leader peptide fused to apolipophorin III residues 1-91 was 
directed to the periplasm of E. coli cells when cultured. Here, peptidase cleaving activity generated 
the N-terminal cysteine. The two fusion proteins, apolipoprotein E-intein-CBD and pelB-
apolipophorin III, were successfully ligated to yield a fusion hybrid apolipoprotein.69  
Another prospective method to overlap fusion PCR is the PCR cut-and-ligate method to 
ligate them together as a single gene. Webb et. al. used this method to fuse GFP with various 
proteins involved in the sporulation in Bacillus subtilis. The gene for GFP was fused with sspE-
2g, cotE, csfB, and gerE. GFP was ligated into pBluescriptSKII, generating pCW8. Using this 
plasmid, the other genes were amplified via PCR, digested with restriction enzymes, and ligated 
upstream of GFP into pCW8 to generate other plasmids to be used in the studies. By removing the 
stop codons of the various other genes, they would be transcribed as GFP fusion constructs, 
allowing the observation and localization of the proteins involved in sporulation.70 More recently, 
a similar fusion method was used in which a plasmid containing GFP had biotin protein ligase 
ligated into it to fuse GFP and biotin protein ligase, allowing for the detection of Cu2+ and Zn2+ 
cations in aqueous solution.71 A method similar to this was also used by the Puckett research group 
to fuse the genes for organophosphorus hydrolase (OPH) and EGFP. OPH and EGFP were 
individually amplified via PCR with an XhoI restriction site added to each one, HindIII added to 
one gene, and EcoRI added to the other. The two pieces were then digested with XhoI and ligated 
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together at the restriction site. A second digestion and ligation are performed using EcoRI and 
HindIII with the pFLAG-MAC vector, resulting in the ligation of the fusion construct into the 
vector for expression. The genes for β-lactamase and EGFP could be individually amplified via 
PCR with the restriction sites added to the ends using primers, and digested. The two could then 
be ligated together to create the fusion construct, without the need for overlap PCR being 
performed. Once the fusion gene was constructed, using a different set of restriction enzymes so 
as not to cleave the construct, the fusion gene and vector plasmid could be digested and then ligated 
together to create the desired recombinant plasmid. Alternatively, EGFP could be ligated into a 
plasmid, and then β-lactamase could be ligated in upstream with the stop codon removed, allowing 
for the continuous transcription and translation of the fusion protein. After successfully ligating 
the fusion gene, a single fusion protein would be transcribed and translated by bacterial cells, 
allowing fluorescence studies to be performed. Figure 31 below depicts a summary the PCR cut-
and-ligate method that could be used for the creation of the in vivo fusion construct to be ligated 
into the pET28b vector. 
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Figure 31. β-lactamase and EGFP PCR cut-and-ligate method 
 
A final consideration for alternative methodology is the use of USER (uracil-specific 
excision reagent) fusion. Geu-Flores et. al. demonstrated the use of USER fusion to combine the 
fusion of three PCR products into one with the cloning of the fusion product into a vector in one 
step, as opposed to two PCR setups, a digestion, and a ligation. When performing overlap 
extension PCR, multiple PCR setups must be run, introducing the opportunity for human and 
instrument error. In their experimentation, Geu-Flores et. al. amplified three DNA sequences 
individually using Pfu Turbo. The primers of the three individual sequences contained 
complementary overhangs for the fusion of the genes. The purified the products with Qiagen 
QIAquick PCR purification kit. The PCR products, along with a stock of PacI/Nt.BbvCI pre-
digested plasmid, were run on an agarose gel to estimate concentration, and they mixed them in a 
10:10:10:1 molar ratio (with 10 being amplicons and 1 being the digested vector plasmid). The 
mixtures were treated with USERTM enzyme mix. USERTM enzyme mix contains uracil DNA 
glycosylase and DNA glycosylase-lyase endonuclease VIII. The result was a successful fusion and 
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ligation of the three sequences into a pre-digested vector in one step requiring only one hour.72 
While this method seems promising, it is recommended first investing time in the use of Pfu or 
Phusion polymerase an optimizing the PCR protocols for those enzymes, as it would likely be the 
simplest solution for the issues faced in the research with the least amount of change in 
methodology. As Taq is an inefficient enzyme for larger constructs, this should improve the future 
success of the project. 
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